News Updates
Incubate’s Investment Tracker measures the impacts of the Inflation Reduction Act’s healthcare provisions on the life sciences ecosystem, with special attention to the impacts of the small molecule penalty.
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead is letting go of 34 employees at its Oceanside, California, site.
Takeda
Layoffs
Cambridge, MA
50,001+ employees
Takeda is laying off 243 employees across its U.S. operations, an effort that will heavily affect its neuroscience commercialization teams.The spokesperson told the media outlet the workforce reduction was part of a “strategic decision” to help the company navigate its upcoming loss of exclusivity for Trintellix, a major depressive disorder drug. That decision also includes “reprioritizing resources to prepare for multiple potential new medication launches in the U.S.”
Vedanta Biosciences
Layoffs
Cambridge, MA
51-200 employees
Vedanta Biosciences “significantly” reduced its headcount to maintain progress and focus resources on a Phase III study of oral drug candidate VE303 for recurrent Clostridioides difficile infection (rCDI).
EMD Serono
Layoffs
Boston, MA
1,001-5,000 employees
EMD Serono, the U.S. division of Merck KGaA, is parting ways with an undisclosed number of employees. The layoffs will affect research staff at the company’s offices in Durham, North Carolina.
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
A month after announcing a partnership with Regeneron to advance its lead gene editor, Tessera Therapeutics has disclosed it will lay off 90 employees. Endpoints News first reported the cuts. Several employees told Endpoints the layoffs will affect about 35% of the workforce. The cuts follow a 17% reduction in 2025 and 13% downsizing in 2024.
GSK
Layoffs
San Francisco, CA
50,001+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK, according to Fierce.
Voyager Therapeutics
Layoffs
Lexington, MA
51-200 employees
Voyager let 30 employees go, according to reporting from Fierce Biotech.
Intercept Pharmaceuticals
Layoffs
Morristown, NJ
201-500 employees
Months after withdrawing its only commercial product, Ocaliva, from the market, Intercept Pharmaceuticals is letting go of 146 employees from its New Jersey campus, according to a Worker Adjustment and Retraining Notification (WARN) Act posting.
Geron Corporation
Layoffs
Foster City, CA
51-200 employees
In a bid to reinvigorate sales of its cancer therapy Rytelo, Geron is reducing its headcount by a third and said it will use the savings to strengthen its commercial strategy and execution for the drug. The company currently has about 260 employees, so the layoffs will affect about 87 people, according to a Thursday news release.